Parkinson’s disease is a complex slowly progressive neurodegenerative disorder with motor and non-motor symptoms affecting daily living. Despite effective symptomatic treatments, with various degrees of side effects, no disease-modifying therapeutic options presently exist. Symptoms progress, with an accumulating burden, reducing the quality of life and forming the impression that medications are no longer effective. Adopting positive lifestyle behaviours can empower patients, improve the quality of life, alleviate symptoms, and potentially slow disease progression. Lifestyle behaviours including nutrition, cognitive enrichment, physical activity, and stress management have beneficial effects on brain health and quality of life. While some evidence of an association of lifestyle with Parkinson’s disease risk and progression exists, the sparse and often conflicting data make it difficult to provide clinical recommendations. Herein, we highlight studies showing promising associations between lifestyle and Parkinson’s disease. Given the increasing aging of populations worldwide and the prevalence of neurological disorders, further research into self-management through adoption of positive lifestyle behaviours is clearly warranted to better enable individualized care.

1.
Hughes
AJ
,
Daniel
SE
,
Kilford
L
,
Lees
AJ
.
Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases
.
J Neurol Neurosurg Psychiatry
.
1992
Mar
;
55
(
3
):
181
4
.
[PubMed]
0022-3050
2.
Turcano
P
,
Mielke
MM
,
Bower
JH
,
Parisi
JE
,
Cutsforth-Gregory
JK
,
Ahlskog
JE
, et al.
Levodopa-induced dyskinesia in Parkinson disease: A population-based cohort study
.
Neurology
.
2018
Dec
;
91
(
24
):
e2238
43
.
[PubMed]
0028-3878
3.
Fahn
S
,
Oakes
D
,
Shoulson
I
,
Kieburtz
K
,
Rudolph
A
,
Lang
A
, et al.;
Parkinson Study Group
.
Levodopa and the progression of Parkinson’s disease
.
N Engl J Med
.
2004
Dec
;
351
(
24
):
2498
508
.
[PubMed]
0028-4793
4.
Lee
DJ
,
Dallapiazza
RF
,
De Vloo
P
,
Lozano
AM
.
Current surgical treatments for Parkinson’s disease and potential therapeutic targets
.
Neural Regen Res
.
2018
Aug
;
13
(
8
):
1342
5
.
[PubMed]
1673-5374
5.
Axelsen
TM
,
Woldbye
DP
.
Gene Therapy for Parkinson’s Disease, An Update
.
J Parkinsons Dis
.
2018
;
8
(
2
):
195
215
.
[PubMed]
1877-7171
6.
Charvin
D
,
Medori
R
,
Hauser
RA
,
Rascol
O
.
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
.
Nat Rev Drug Discov
.
2018
;
17
(
11
):
804
22
. 1474-1776
7.
Yasuhara
T
,
Kameda
M
,
Sasaki
T
,
Tajiri
N
,
Date
I
.
Cell Therapy for Parkinson’s Disease
.
Cell Transplant
.
2017
Sep
;
26
(
9
):
1551
9
.
[PubMed]
0963-6897
8.
Wang
HJ
,
Tan
G
,
Zhu
LN
,
Chen
D
,
Xu
D
,
Chu
SS
, et al.
The efficacy of repetitive transcranial magnetic stimulation for Parkinson disease patients with depression
.
Int J Neurosci
.
2018
Jul
;
•••
:
1
24
.
[PubMed]
0020-7454
9.
Chung
CL
,
Mak
MK
.
Effect of Repetitive Transcranial Magnetic Stimulation on Physical Function and Motor Signs in Parkinson’s Disease: A Systematic Review and Meta-Analysis
.
Brain Stimul
.
2016
Jul-Aug
;
9
(
4
):
475
87
.
[PubMed]
1935-861X
10.
Chou
YH
,
Hickey
PT
,
Sundman
M
,
Song
AW
,
Chen
NK
.
Effects of repetitive transcranial magnetic stimulation on motor symptoms in Parkinson disease: a systematic review and meta-analysis
.
JAMA Neurol
.
2015
Apr
;
72
(
4
):
432
40
.
[PubMed]
2168-6149
11.
Yang
C
,
Guo
Z
,
Peng
H
,
Xing
G
,
Chen
H
,
McClure
MA
, et al.
Repetitive transcranial magnetic stimulation therapy for motor recovery in Parkinson’s disease: A Meta-analysis
.
Brain Behav
.
2018
Nov
;
8
(
11
):
e01132
.
[PubMed]
2162-3279
12.
Lattari
E
,
Costa
SS
,
Campos
C
,
de Oliveira
AJ
,
Machado
S
,
Maranhao Neto
GA
.
Can transcranial direct current stimulation on the dorsolateral prefrontal cortex improves balance and functional mobility in Parkinson’s disease?
Neurosci Lett
.
2017
Jan
;
636
:
165
9
.
[PubMed]
0304-3940
13.
Ishikuro
K
,
Dougu
N
,
Nukui
T
,
Yamamoto
M
,
Nakatsuji
Y
,
Kuroda
S
, et al.
Effects of Transcranial Direct Current Stimulation (tDCS) Over the Frontal Polar Area on Motor and Executive Functions in Parkinson’s Disease; A Pilot Study
.
Front Aging Neurosci
.
2018
Jul
;
10
:
231
.
[PubMed]
1663-4365
14.
Kelly
E
,
Vyas
P
,
Weber
JT
.
Biochemical Properties and Neuroprotective Effects of Compounds in Various Species of Berries
.
Basel
:
Molecules
;
2017
. p.
23
.
15.
Islam
MT
,
Tabrez
S
,
Jabir
NR
,
Ali
M
,
Kamal
MA
,
da Silva Araujo
L
, et al.
An Insight into the Therapeutic Potential of Major Coffee Components
.
Curr Drug Metab
.
2018
;
19
(
6
):
544
56
.
[PubMed]
1389-2002
16.
Morelli
M
,
Carta
AR
,
Kachroo
A
,
Schwarzschild
MA
.
Pathophysiological roles for purines: adenosine, caffeine and urate
.
Prog Brain Res
.
2010
;
183
:
183
208
.
[PubMed]
0079-6123
17.
Abbas
MM
,
Xu
Z
,
Tan
LC
.
Epidemiology of Parkinson’s Disease-East Versus West
.
Mov Disord Clin Pract (Hoboken)
.
2017
Dec
;
5
(
1
):
14
28
.
[PubMed]
2330-1619
18.
Santangelo
G
,
Garramone
F
,
Baiano
C
,
D’Iorio
A
,
Piscopo
F
,
Raimo
S
, et al.
Personality and Parkinson’s disease: A meta-analysis
.
Parkinsonism Relat Disord
.
2018
Apr
;
49
:
67
74
.
[PubMed]
1353-8020
19.
Vecchio
LM
,
Meng
Y
,
Xhima
K
,
Lipsman
N
,
Hamani
C
,
Aubert
I
.
The Neuroprotective Effects of Exercise: Maintaining a Healthy Brain Throughout Aging
.
Brain Plast
.
2018
Dec
;
4
(
1
):
17
52
.
[PubMed]
2213-6304
20.
Kwok
JY
,
Choi
KC
,
Chan
HY
.
Effects of mind-body exercises on the physiological and psychosocial well-being of individuals with Parkinson’s disease: A systematic review and meta-analysis
.
Complement Ther Med
.
2016
Dec
;
29
:
121
31
.
[PubMed]
0965-2299
21.
Van Puymbroeck
M
,
Walter
AA
,
Hawkins
BL
,
Sharp
JL
,
Woschkolup
K
,
Urrea-Mendoza
E
, et al.
Functional Improvements in Parkinson’s Disease Following a Randomized Trial of Yoga
.
Evid Based Complement Alternat Med
.
2018
Jun
;
2018
:
8516351
.
[PubMed]
1741-427X
22.
Ni
M
,
Mooney
K
,
Signorile
JF
.
Controlled pilot study of the effects of power yoga in Parkinson’s disease
.
Complement Ther Med
.
2016
Apr
;
25
:
126
31
.
[PubMed]
0965-2299
23.
Li
F
,
Harmer
P
,
Fitzgerald
K
,
Eckstrom
E
,
Stock
R
,
Galver
J
, et al.
Tai chi and postural stability in patients with Parkinson’s disease
.
N Engl J Med
.
2012
Feb
;
366
(
6
):
511
9
.
[PubMed]
0028-4793
24.
Yang
Y
,
Qiu
WQ
,
Hao
YL
,
Lv
ZY
,
Jiao
SJ
,
Teng
JF
.
The efficacy of traditional Chinese Medical Exercise for Parkinson’s disease: a systematic review and meta-analysis
.
PLoS One
.
2015
Apr
;
10
(
4
):
e0122469
.
[PubMed]
1932-6203
25.
Dos Santos Delabary
M
,
Komeroski
IG
,
Monteiro
EP
,
Costa
RR
,
Haas
AN
.
Effects of dance practice on functional mobility, motor symptoms and quality of life in people with Parkinson’s disease: a systematic review with meta-analysis
.
Aging Clin Exp Res
.
2018
Jul
;
30
(
7
):
727
35
.
[PubMed]
1594-0667
26.
Xiao
CM
,
Zhuang
YC
.
Effect of health Baduanjin Qigong for mild to moderate Parkinson’s disease
.
Geriatr Gerontol Int
.
2016
Aug
;
16
(
8
):
911
9
.
[PubMed]
1444-1586
27.
Stegemöller
EL
,
Hibbing
P
,
Radig
H
,
Wingate
J
.
Therapeutic singing as an early intervention for swallowing in persons with Parkinson’s disease
.
Complement Ther Med
.
2017
Apr
;
31
:
127
33
.
[PubMed]
0965-2299
28.
Abell
RV
,
Baird
AD
,
Chalmers
KA
.
Group singing and health-related quality of life in Parkinson’s disease
.
Health Psychol
.
2017
Jan
;
36
(
1
):
55
64
.
[PubMed]
0278-6133
29.
García-Casares
N
,
Martín-Colom
JE
,
García-Arnés
JA
.
Music Therapy in Parkinson’s Disease
.
J Am Med Dir Assoc
.
2018
Dec
;
19
(
12
):
1054
62
.
[PubMed]
1525-8610
30.
McKenzie
JA
,
Spielman
LJ
,
Pointer
CB
,
Lowry
JR
,
Bajwa
E
,
Lee
CW
, et al.
Neuroinflammation as a Common Mechanism Associated with the Modifiable Risk Factors for Alzheimer’s and Parkinson’s Diseases
.
Curr Aging Sci
.
2017
;
10
(
3
):
158
76
.
[PubMed]
1874-6128
31.
Chen
H
,
Zhang
SM
,
Schwarzschild
MA
,
Hernán
MA
,
Ascherio
A
.
Physical activity and the risk of Parkinson disease
.
Neurology
.
2005
Feb
;
64
(
4
):
664
9
.
[PubMed]
0028-3878
32.
Xu
Q
,
Park
Y
,
Huang
X
,
Hollenbeck
A
,
Blair
A
,
Schatzkin
A
, et al.
Physical activities and future risk of Parkinson disease
.
Neurology
.
2010
Jul
;
75
(
4
):
341
8
.
[PubMed]
0028-3878
33.
Yang
F
,
Trolle Lagerros
Y
,
Bellocco
R
,
Adami
HO
,
Fang
F
,
Pedersen
NL
, et al.
Physical activity and risk of Parkinson’s disease in the Swedish National March Cohort
.
Brain
.
2015
Feb
;
138
(
Pt 2
):
269
75
.
[PubMed]
0006-8950
34.
Rafferty
MR
,
Schmidt
PN
,
Luo
ST
,
Li
K
,
Marras
C
,
Davis
TL
, et al.;
all NPF-QII Investigators
.
Regular Exercise, Quality of Life, and Mobility in Parkinson’s Disease: A Longitudinal Analysis of National Parkinson Foundation Quality Improvement Initiative Data
.
J Parkinsons Dis
.
2017
;
7
(
1
):
193
202
.
[PubMed]
1877-7171
35.
Prodoehl
J
,
Rafferty
MR
,
David
FJ
,
Poon
C
,
Vaillancourt
DE
,
Comella
CL
, et al.
Two-year exercise program improves physical function in Parkinson’s disease: the PRET-PD randomized clinical trial
.
Neurorehabil Neural Repair
.
2015
Feb
;
29
(
2
):
112
22
.
[PubMed]
1545-9683
36.
Corcos
DM
,
Robichaud
JA
,
David
FJ
,
Leurgans
SE
,
Vaillancourt
DE
,
Poon
C
, et al.
A two-year randomized controlled trial of progressive resistance exercise for Parkinson’s disease
.
Mov Disord
.
2013
Aug
;
28
(
9
):
1230
40
.
[PubMed]
0885-3185
37.
Cascaes da Silva
F
,
Iop Rda
R
,
Domingos Dos Santos
P
,
Aguiar Bezerra de Melo
LM
,
Barbosa Gutierres Filho
PJ
,
da Silva
R
.
Effects of Physical-Exercise-Based Rehabilitation Programs on the Quality of Life of Patients With Parkinson’s Disease: A Systematic Review of Randomized Controlled Trials
.
J Aging Phys Act
.
2016
Jul
;
24
(
3
):
484
96
.
[PubMed]
1063-8652
38.
Reuter
I
,
Mehnert
S
,
Leone
P
,
Kaps
M
,
Oechsner
M
,
Engelhardt
M
.
Effects of a flexibility and relaxation programme, walking, and nordic walking on Parkinson’s disease
.
J Aging Res
.
2011
;
2011
:
232473
.
[PubMed]
2090-2204
39.
Uc
EY
,
Doerschug
KC
,
Magnotta
V
,
Dawson
JD
,
Thomsen
TR
,
Kline
JN
, et al.
Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting
.
Neurology
.
2014
Jul
;
83
(
5
):
413
25
.
[PubMed]
0028-3878
40.
Mak
MK
,
Wong-Yu
IS
,
Shen
X
,
Chung
CL
.
Long-term effects of exercise and physical therapy in people with Parkinson disease
.
Nat Rev Neurol
.
2017
Nov
;
13
(
11
):
689
703
.
[PubMed]
1759-4758
41.
Shulman
LM
,
Katzel
LI
,
Ivey
FM
,
Sorkin
JD
,
Favors
K
,
Anderson
KE
, et al.
Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease
.
JAMA Neurol
.
2013
Feb
;
70
(
2
):
183
90
.
[PubMed]
2168-6149
42.
Nadeau
A
,
Pourcher
E
,
Corbeil
P
.
Effects of 24 wk of treadmill training on gait performance in Parkinson’s disease
.
Med Sci Sports Exerc
.
2014
Apr
;
46
(
4
):
645
55
.
[PubMed]
0195-9131
43.
Bombieri
F
,
Schena
F
,
Pellegrini
B
,
Barone
P
,
Tinazzi
M
,
Erro
R
.
Walking on four limbs: A systematic review of Nordic Walking in Parkinson disease
.
Parkinsonism Relat Disord
.
2017
May
;
38
:
8
12
.
[PubMed]
1353-8020
44.
Ramazzina
I
,
Bernazzoli
B
,
Costantino
C
.
Systematic review on strength training in Parkinson’s disease: an unsolved question
.
Clin Interv Aging
.
2017
Mar
;
12
:
619
28
.
[PubMed]
1176-9092
45.
Saltychev
M
,
Bärlund
E
,
Paltamaa
J
,
Katajapuu
N
,
Laimi
K
.
Progressive resistance training in Parkinson’s disease: a systematic review and meta-analysis
.
BMJ Open
.
2016
Jan
;
6
(
1
):
e008756
.
[PubMed]
2044-6055
46.
Morris
ME
,
Iansek
R
,
Kirkwood
B
.
A randomized controlled trial of movement strategies compared with exercise for people with Parkinson’s disease
.
Mov Disord
.
2009
Jan
;
24
(
1
):
64
71
.
[PubMed]
0885-3185
47.
Ribas
CG
,
Alves da Silva
L
,
Corrêa
MR
,
Teive
HG
,
Valderramas
S
.
Effectiveness of exergaming in improving functional balance, fatigue and quality of life in Parkinson’s disease: A pilot randomized controlled trial
.
Parkinsonism Relat Disord
.
2017
May
;
38
:
13
8
.
[PubMed]
1353-8020
48.
Yang
WC
,
Wang
HK
,
Wu
RM
,
Lo
CS
,
Lin
KH
.
Home-based virtual reality balance training and conventional balance training in Parkinson’s disease: A randomized controlled trial
.
J Formos Med Assoc
.
2016
Sep
;
115
(
9
):
734
43
.
[PubMed]
0929-6646
49.
Jakowec
MW
,
Wang
Z
,
Holschneider
D
,
Beeler
J
,
Petzinger
GM
.
Engaging cognitive circuits to promote motor recovery in degenerative disorders. exercise as a learning modality
.
J Hum Kinet
.
2016
Sep
;
52
(
1
):
35
51
.
[PubMed]
1640-5544
50.
Hughes
KC
,
Gao
X
,
Kim
IY
,
Wang
M
,
Weisskopf
MG
,
Schwarzschild
MA
, et al.
Intake of dairy foods and risk of Parkinson disease
.
Neurology
.
2017
Jul
;
89
(
1
):
46
52
.
[PubMed]
0028-3878
51.
Park
M
,
Ross
GW
,
Petrovitch
H
,
White
LR
,
Masaki
KH
,
Nelson
JS
, et al.
Consumption of milk and calcium in midlife and the future risk of Parkinson disease
.
Neurology
.
2005
Mar
;
64
(
6
):
1047
51
.
[PubMed]
0028-3878
52.
Chen
H
,
O’Reilly
E
,
McCullough
ML
,
Rodriguez
C
,
Schwarzschild
MA
,
Calle
EE
, et al.
Consumption of dairy products and risk of Parkinson’s disease
.
Am J Epidemiol
.
2007
May
;
165
(
9
):
998
1006
.
[PubMed]
0002-9262
53.
Sääksjärvi
K
,
Knekt
P
,
Lundqvist
A
,
Männistö
S
,
Heliövaara
M
,
Rissanen
H
, et al.
A cohort study on diet and the risk of Parkinson’s disease: the role of food groups and diet quality
.
Br J Nutr
.
2013
Jan
;
109
(
2
):
329
37
.
[PubMed]
0007-1145
54.
Kyrozis
A
,
Ghika
A
,
Stathopoulos
P
,
Vassilopoulos
D
,
Trichopoulos
D
,
Trichopoulou
A
.
Dietary and lifestyle variables in relation to incidence of Parkinson’s disease in Greece
.
Eur J Epidemiol
.
2013
Jan
;
28
(
1
):
67
77
.
[PubMed]
0393-2990
55.
Choi
HK
,
Atkinson
K
,
Karlson
EW
,
Willett
W
,
Curhan
G
.
Purine-rich foods, dairy and protein intake, and the risk of gout in men
.
N Engl J Med
.
2004
Mar
;
350
(
11
):
1093
103
.
[PubMed]
0028-4793
56.
Gao
X
,
Chen
H
,
Choi
HK
,
Curhan
G
,
Schwarzschild
MA
,
Ascherio
A
.
Diet, urate, and Parkinson’s disease risk in men
.
Am J Epidemiol
.
2008
Apr
;
167
(
7
):
831
8
.
[PubMed]
0002-9262
57.
Ascherio
A
,
LeWitt
PA
,
Xu
K
,
Eberly
S
,
Watts
A
,
Matson
WR
, et al.;
Parkinson Study Group DATATOP Investigators
.
Urate as a predictor of the rate of clinical decline in Parkinson disease
.
Arch Neurol
.
2009
Dec
;
66
(
12
):
1460
8
.
[PubMed]
0003-9942
58.
Allen
MT
,
Levy
LS
.
Parkinson’s disease and pesticide exposure—a new assessment
.
Crit Rev Toxicol
.
2013
Jul
;
43
(
6
):
515
34
.
[PubMed]
1040-8444
59.
Martin
M
,
Dotti
CG
,
Ledesma
MD
.
Brain cholesterol in normal and pathological aging
.
Biochim Biophys Acta
.
2010
Aug
;
1801
(
8
):
934
44
.
[PubMed]
0006-3002
60.
Huang
X
,
Abbott
RD
,
Petrovitch
H
,
Mailman
RB
,
Ross
GW
.
Low LDL cholesterol and increased risk of Parkinson’s disease: prospective results from Honolulu-Asia Aging Study
.
Mov Disord
.
2008
May
;
23
(
7
):
1013
8
.
[PubMed]
0885-3185
61.
Simon
KC
,
Chen
H
,
Schwarzschild
M
,
Ascherio
A
.
Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease
.
Neurology
.
2007
Oct
;
69
(
17
):
1688
95
.
[PubMed]
0028-3878
62.
Rozani
V
,
Gurevich
T
,
Giladi
N
,
El-Ad
B
,
Tsamir
J
,
Hemo
B
, et al.
Higher serum cholesterol and decreased Parkinson’s disease risk: A statin-free cohort study
.
Mov Disord
.
2018
Aug
;
33
(
8
):
1298
305
.
[PubMed]
0885-3185
63.
de Lau
LM
,
Koudstaal
PJ
,
Hofman
A
,
Breteler
MM
.
Serum cholesterol levels and the risk of Parkinson’s disease
.
Am J Epidemiol
.
2006
Nov
;
164
(
10
):
998
1002
.
[PubMed]
0002-9262
64.
Hu
G
,
Antikainen
R
,
Jousilahti
P
,
Kivipelto
M
,
Tuomilehto
J
.
Total cholesterol and the risk of Parkinson disease
.
Neurology
.
2008
May
;
70
(
21
):
1972
9
.
[PubMed]
0028-3878
65.
Gudala
K
,
Bansal
D
,
Muthyala
H
.
Role of serum cholesterol in Parkinson’s disease: a meta-analysis of evidence
.
J Parkinsons Dis
.
2013
Jan
;
3
(
3
):
363
70
.
[PubMed]
1877-718X
66.
Hu
G
,
Jousilahti
P
,
Bidel
S
,
Antikainen
R
,
Tuomilehto
J
.
Type 2 diabetes and the risk of Parkinson’s disease
.
Diabetes Care
.
2007
Apr
;
30
(
4
):
842
7
.
[PubMed]
0149-5992
67.
Schernhammer
E
,
Hansen
J
,
Rugbjerg
K
,
Wermuth
L
,
Ritz
B
.
Diabetes and the risk of developing Parkinson’s disease in Denmark
.
Diabetes Care
.
2011
May
;
34
(
5
):
1102
8
.
[PubMed]
0149-5992
68.
Sun
Y
,
Chang
YH
,
Chen
HF
,
Su
YH
,
Su
HF
,
Li
CY
.
Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications
.
Diabetes Care
.
2012
May
;
35
(
5
):
1047
9
.
[PubMed]
0149-5992
69.
Palacios
N
,
Gao
X
,
McCullough
ML
,
Jacobs
EJ
,
Patel
AV
,
Mayo
T
, et al.
Obesity, diabetes, and risk of Parkinson’s disease
.
Mov Disord
.
2011
Oct
;
26
(
12
):
2253
9
.
[PubMed]
0885-3185
70.
Xu
Q
,
Park
Y
,
Huang
X
,
Hollenbeck
A
,
Blair
A
,
Schatzkin
A
, et al.
Diabetes and risk of Parkinson’s disease
.
Diabetes Care
.
2011
Apr
;
34
(
4
):
910
5
.
[PubMed]
0149-5992
71.
Kim
IY
,
O’Reilly
EJ
,
Hughes
KC
,
Gao
X
,
Schwarzschild
MA
,
Ascherio
A
.
Differences in Parkinson’s Disease Risk with Caffeine Intake and Postmenopausal Hormone Use
.
J Parkinsons Dis
.
2017
;
7
(
4
):
677
84
.
[PubMed]
1877-7171
72.
Ross
GW
,
Abbott
RD
,
Petrovitch
H
,
Morens
DM
,
Grandinetti
A
,
Tung
KH
, et al.
Association of coffee and caffeine intake with the risk of Parkinson disease
.
JAMA
.
2000
May
;
283
(
20
):
2674
9
.
[PubMed]
0098-7484
73.
Hernán
MA
,
Takkouche
B
,
Caamaño-Isorna
F
,
Gestal-Otero
JJ
.
A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease
.
Ann Neurol
.
2002
Sep
;
52
(
3
):
276
84
.
[PubMed]
0364-5134
74.
Costa
J
,
Lunet
N
,
Santos
C
,
Santos
J
,
Vaz-Carneiro
A
.
Caffeine exposure and the risk of Parkinson’s disease: a systematic review and meta-analysis of observational studies
.
J Alzheimers Dis
.
2010
;
20
(
s1
Suppl 1
):
S221
38
.
[PubMed]
1387-2877
75.
Fowler
JS
,
Volkow
ND
,
Wang
GJ
,
Pappas
N
,
Logan
J
,
MacGregor
R
, et al.
Inhibition of monoamine oxidase B in the brains of smokers
.
Nature
.
1996
Feb
;
379
(
6567
):
733
6
.
[PubMed]
0028-0836
76.
Thacker
EL
,
O’Reilly
EJ
,
Weisskopf
MG
,
Chen
H
,
Schwarzschild
MA
,
McCullough
ML
, et al.
Temporal relationship between cigarette smoking and risk of Parkinson disease
.
Neurology
.
2007
Mar
;
68
(
10
):
764
8
.
[PubMed]
0028-3878
77.
Chen
H
,
Huang
X
,
Guo
X
,
Mailman
RB
,
Park
Y
,
Kamel
F
, et al.
Smoking duration, intensity, and risk of Parkinson disease
.
Neurology
.
2010
Mar
;
74
(
11
):
878
84
.
[PubMed]
0028-3878
78.
Nielsen
SS
,
Franklin
GM
,
Longstreth
WT
,
Swanson
PD
,
Checkoway
H
.
Nicotine from edible Solanaceae and risk of Parkinson disease
.
Ann Neurol
.
2013
Sep
;
74
(
3
):
472
7
.
[PubMed]
0364-5134
79.
Mischley
LK
,
Lau
RC
,
Bennett
RD
.
Role of Diet and Nutritional Supplements in Parkinson’s Disease Progression
.
Oxid Med Cell Longev
.
2017
;
2017
:
6405278
.
[PubMed]
1942-0900
80.
Guo
JD
,
Zhao
X
,
Li
Y
,
Li
GR
,
Liu
XL
.
Damage to dopaminergic neurons by oxidative stress in Parkinson’s disease (Review)
.
[Review]
.
Int J Mol Med
.
2018
Apr
;
41
(
4
):
1817
25
.
[PubMed]
1107-3756
81.
Davis
JW
,
Grandinetti
A
,
Waslien
CI
,
Ross
GW
,
White
LR
,
Morens
DM
.
Observations on serum uric acid levels and the risk of idiopathic Parkinson’s disease
.
Am J Epidemiol
.
1996
Sep
;
144
(
5
):
480
4
.
[PubMed]
0002-9262
82.
Weisskopf
MG
,
O’Reilly
E
,
Chen
H
,
Schwarzschild
MA
,
Ascherio
A
.
Plasma urate and risk of Parkinson’s disease
.
Am J Epidemiol
.
2007
Sep
;
166
(
5
):
561
7
.
[PubMed]
0002-9262
83.
de Lau
LM
,
Koudstaal
PJ
,
Hofman
A
,
Breteler
MM
.
Serum uric acid levels and the risk of Parkinson disease
.
Ann Neurol
.
2005
Nov
;
58
(
5
):
797
800
.
[PubMed]
0364-5134
84.
O’Reilly
EJ
,
Gao
X
,
Weisskopf
MG
,
Chen
H
,
Schwarzschild
MA
,
Spiegelman
D
, et al.
Plasma urate and Parkinson’s disease in women
.
Am J Epidemiol
.
2010
Sep
;
172
(
6
):
666
70
.
[PubMed]
0002-9262
85.
Solanki
I
,
Parihar
P
,
Parihar
MS
.
Neurodegenerative diseases: from available treatments to prospective herbal therapy
.
Neurochem Int
.
2016
May
;
95
:
100
8
.
[PubMed]
0197-0186
86.
Gao
X
,
Cassidy
A
,
Schwarzschild
MA
,
Rimm
EB
,
Ascherio
A
.
Habitual intake of dietary flavonoids and risk of Parkinson disease
.
Neurology
.
2012
Apr
;
78
(
15
):
1138
45
.
[PubMed]
0028-3878
87.
Gao
X
,
Chen
H
,
Fung
TT
,
Logroscino
G
,
Schwarzschild
MA
,
Hu
FB
, et al.
Prospective study of dietary pattern and risk of Parkinson disease
.
Am J Clin Nutr
.
2007
Nov
;
86
(
5
):
1486
94
.
[PubMed]
0002-9165
88.
Villafane
G
,
Thiriez
C
,
Audureau
E
,
Straczek
C
,
Kerschen
P
,
Cormier-Dequaire
F
, et al.
High-dose transdermal nicotine in Parkinson’s disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study
.
Eur J Neurol
.
2018
Jan
;
25
(
1
):
120
7
.
[PubMed]
1351-5101
89.
Postuma
RB
,
Anang
J
,
Pelletier
A
,
Joseph
L
,
Moscovich
M
,
Grimes
D
, et al.
Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial
.
Neurology
.
2017
Oct
;
89
(
17
):
1795
803
.
[PubMed]
0028-3878
90.
Ascherio
A
,
LeWitt
PA
,
Xu
K
,
Eberly
S
,
Watts
A
,
Matson
WR
, et al.;
Parkinson Study Group DATATOP Investigators
.
Urate as a predictor of the rate of clinical decline in Parkinson disease
.
Arch Neurol
.
2009
Dec
;
66
(
12
):
1460
8
.
[PubMed]
0003-9942
91.
Schwarzschild
MA
,
Schwid
SR
,
Marek
K
,
Watts
A
,
Lang
AE
,
Oakes
D
, et al.;
Parkinson Study Group PRECEPT Investigators
.
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease
.
Arch Neurol
.
2008
Jun
;
65
(
6
):
716
23
.
[PubMed]
0003-9942
92.
Parkinson Study Group S-PDI
.
Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K: Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial
.
JAMA Neurol
.
2014
;
71
:
141
50
.2168-6149
93.
Group
PS
;
Parkinson Study Group
.
Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa
.
Ann Neurol
.
1996
Jan
;
39
(
1
):
37
45
.
[PubMed]
0364-5134
94.
94Parkinson Study Group QEI, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K: A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol 2014;71:543-552.
95.
NINDS NET-PD Investigators
.
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease
.
Neurology
.
2006
Mar
;
66
(
5
):
664
71
.
[PubMed]
0028-3878
96.
NINDS NET-PD Investigators
.
A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results
.
Clin Neuropharmacol
.
2008
May-Jun
;
31
(
3
):
141
50
.
[PubMed]
0362-5664
97.
Writing Group for the NETiPDI
.
Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB, Jr., Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Perez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM: Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial
.
JAMA
.
2015
;
313
:
584
93
.0098-7484
98.
Kim
IY
,
O’Reilly
EJ
,
Hughes
KC
,
Gao
X
,
Schwarzschild
MA
,
Hannan
MT
, et al.
Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts
.
Neurology
.
2018
May
;
90
(
19
):
e1646
53
.
[PubMed]
0028-3878
99.
Livingston
G
,
Sommerlad
A
,
Orgeta
V
,
Costafreda
SG
,
Huntley
J
,
Ames
D
, et al.
Dementia prevention, intervention, and care
.
Lancet
.
2017
Dec
;
390
(
10113
):
2673
734
.
[PubMed]
0140-6736
100.
Mollenhauer
B
,
Zimmermann
J
,
Sixel-Döring
F
,
Focke
NK
,
Wicke
T
,
Ebentheuer
J
, et al.;
DeNoPa Study Group
.
Baseline predictors for progression 4 years after Parkinson’s disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)
.
Mov Disord
.
2019
Jan
;
34
(
1
):
67
77
.
[PubMed]
0885-3185
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.